—— CEO Anthony Sun M.D.
Since its creation in 2020, Zentera has been cultivating an experienced and efficient team. We collaborate with major hospitals to carry out clinical research in a precise, efficient and high-quality manner. We are committed to the development and commercialization of three oncology assets discovered by Zentalis (ZN-c3, ZN-c5, ZN-d5) in China. At the same time, we continue to discover and identify molecules that are synergistic with the current assets in our pipeline. We believe Zentera has the potential to become a leading biopharmaceutical company providing patients with first-class cancer drugs.